JP2024518826A5 - - Google Patents

Info

Publication number
JP2024518826A5
JP2024518826A5 JP2023570380A JP2023570380A JP2024518826A5 JP 2024518826 A5 JP2024518826 A5 JP 2024518826A5 JP 2023570380 A JP2023570380 A JP 2023570380A JP 2023570380 A JP2023570380 A JP 2023570380A JP 2024518826 A5 JP2024518826 A5 JP 2024518826A5
Authority
JP
Japan
Prior art keywords
cells
immune
responsive
cell according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518826A (ja
Filing date
Publication date
Priority claimed from US17/320,663 external-priority patent/US11766457B2/en
Application filed filed Critical
Publication of JP2024518826A publication Critical patent/JP2024518826A/ja
Publication of JP2024518826A5 publication Critical patent/JP2024518826A5/ja
Pending legal-status Critical Current

Links

JP2023570380A 2021-05-14 2022-05-10 自己免疫障害および同種免疫障害の予防および／または治療のための免疫抑制性抗原特異的キメラ抗原受容体Ｔｒｅｇ細胞 Pending JP2024518826A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/320,663 2021-05-14
US17/320,663 US11766457B2 (en) 2021-05-14 2021-05-14 Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
PCT/US2022/028454 WO2022240797A1 (en) 2021-05-14 2022-05-10 Immunosuppressive antigen-specific chimeric antigen receptor treg cells for prevention and/or treatment of autoimmune and alloimmune disorders

Publications (2)

Publication Number Publication Date
JP2024518826A JP2024518826A (ja) 2024-05-07
JP2024518826A5 true JP2024518826A5 (enExample) 2025-05-13

Family

ID=83999123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570380A Pending JP2024518826A (ja) 2021-05-14 2022-05-10 自己免疫障害および同種免疫障害の予防および／または治療のための免疫抑制性抗原特異的キメラ抗原受容体Ｔｒｅｇ細胞

Country Status (9)

Country Link
US (3) US11766457B2 (enExample)
EP (1) EP4340895A4 (enExample)
JP (1) JP2024518826A (enExample)
KR (1) KR20240007197A (enExample)
CN (1) CN117580594A (enExample)
AU (1) AU2022272620A1 (enExample)
CA (1) CA3218583A1 (enExample)
MX (1) MX2023013487A (enExample)
WO (1) WO2022240797A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434539A1 (en) * 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) * 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2026010984A1 (en) * 2024-07-01 2026-01-08 The University Of Toledo Islet antigen-specific car-t therapy
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
JP7123794B2 (ja) * 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
AU2019377867B2 (en) * 2018-11-08 2026-03-12 The University Of Toledo Immunosuppressive antigen-specific chimeric antigen receptor treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
EP3911371A4 (en) 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
AU2020322221A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)

Similar Documents

Publication Publication Date Title
JP2024518826A5 (enExample)
JP7635291B2 (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP5947727B2 (ja) 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
ES2714381T3 (es) Anticuerpos dirigidos contra ICOS y usos de los mismos
US20210253667A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112020020857A2 (pt) Receptores quiméricos para dll3 e métodos de seu uso
US12435121B2 (en) Compositions and methods for stimulating natural killer cells
KR20210033995A (ko) 인터루킨-2 변이체 및 이의 사용 방법
JP2019530441A5 (enExample)
JP2013517330A (ja) 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells
TW201942132A (zh) 雙特異性抗體
JP2024502479A5 (enExample)
JP2024540275A5 (enExample)
CN116583294A (zh) 抗炎细胞因子及其使用方法
JP2020535811A5 (enExample)
JP7701908B2 (ja) 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
US20230210952A1 (en) Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP3134428B1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
EP4588937A1 (en) Use of nkg2d-based cell adapter molecule in removal of aging cells
US20240207406A1 (en) Methods and compositions comprising mhc class i peptides
CN120166938A (zh) SARS-CoV-2免疫原性组合物和方法
HK40128066A (zh) Sars-cov-2免疫原性组合物和方法
HK1235071B (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
HK1235071A1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer